Oct 5, 2026 05:15PM

Jul 17, 2026 05:31PM

Apr 10, 2026 05:30PM

Feb 19, 2026 05:29PM

Feb 2, 2026 05:30PM

Dec 30, 2025 06:03AM

Aug 19, 2025 08:30AM Propanc Biopharma closes $4 million offering, lists on NASDAQ

Aug 19, 2025 08:30AM

Jul 28, 2025 05:13PM

May 30, 2025 03:40PM

Apr 25, 2025 02:45PM

Apr 8, 2025 05:32PM

Apr 2, 2025 05:27PM

Mar 31, 2025 06:20AM Form S-1/A Propanc Biopharma, Inc.

Oct 30, 2024 06:46AM

Oct 10, 2023 06:43AM

Oct 6, 2023 05:27PM

Aug 11, 2023 05:21PM

Jun 22, 2023 09:00AM

Feb 10, 2022 11:18AM

Feb 3, 2022 04:22PM Form S-1 Propanc Biopharma, Inc.

Dec 14, 2021 09:00AM

Nov 3, 2021 09:00AM

May 17, 2021 09:00AM

Mar 25, 2021 09:00AM

Mar 3, 2021 09:00AM

Feb 15, 2021 09:00AM

Jan 28, 2021 09:00AM Propanc Biopharma Appoints Belen Toledo to Evaluate Impact of Proenzyme Therapy on Tumor Microenvironment

Jan 18, 2021 08:30AM

Jan 11, 2021 08:30AM

Dec 21, 2020 08:30AM

Dec 14, 2020 08:30AM

Nov 3, 2020 05:09PM

Oct 14, 2020 06:03AM

Aug 13, 2020 08:14AM Form S-1/A Propanc Biopharma, Inc.

Jul 28, 2020 08:30AM

Jul 17, 2020 06:04AM

Jun 26, 2020 05:31PM

May 13, 2020 05:51PM

May 11, 2020 08:30AM

Apr 16, 2020 08:30AM

Apr 14, 2020 09:00AM Propanc Biopharma Receives First Allowance for Key Patent Family from Australian Patent Office

Mar 31, 2020 09:00AM

Mar 16, 2020 08:30AM

Jan 24, 2020 05:12PM

Jan 21, 2020 08:30AM

Dec 12, 2019 05:50PM

Nov 18, 2019 08:30AM

Oct 29, 2019 08:30AM Propanc Biopharma Provides Shareholder Update and Forecast for 2020

Oct 21, 2019 08:30AM

68,995 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All